Celularity Inc. (CELU)
Largest Insider Buys in Sector
CELU Stock Price History Chart
CELU Stock Performance
About Celularity Inc.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Insider Activity of Celularity Inc.
Over the last 12 months, insiders at Celularity Inc. have bought $5.33M and sold $0 worth of Celularity Inc. stock.
On average, over the past 5 years, insiders at Celularity Inc. have bought $2.82M and sold $23.06M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lim Kok Thay (10 percent owner) — $5.33M.
The last purchase of 21,410,983 shares for transaction amount of $5.33M was made by Lim Kok Thay (10 percent owner) on 2024‑01‑12.
List of Insider Buy and Sell Transactions, Celularity Inc.
| 2024-01-12 | 10 percent owner | 21.41M 11.8762% | $0.25 | $5.33M | +39.17% | |||
| 2023-10-05 | Sale | 10 percent owner | 6.31M 21.0749% | $1.50 | $9.46M | +42.18% | ||
| 2023-10-05 | Chief Executive Officer | 9.36M 3.306% | $0.16 | $1.48M | +42.18% | |||
| 2023-09-29 | Sale | 10 percent owner | 9.06M 30.2885% | $1.50 | $13.6M | +35.14% | ||
| 2023-09-29 | Chief Executive Officer | 9.06M 3.3418% | $0.17 | $1.5M | +35.14% | |||
| 2022-11-30 | Chief Executive Officer | 10,000 0.0383% | $1.72 | $17,175 | -66.08% | |||
| 2022-11-29 | Chief Executive Officer | 40,000 0.1524% | $1.71 | $68,400 | -65.27% | |||
| 2022-11-28 | Chief Executive Officer | 40,000 0.155% | $1.74 | $69,600 | -64.36% |
Insider Historical Profitability
| Lim Kok Thay | 10 percent owner | 51473762 228.933% | $2.12 | 1 | 0 | |
| Hariri Robert J | Chief Executive Officer | 28570434 127.0689% | $2.12 | 5 | 0 | <0.0001% |
| Sorrento Therapeutics, Inc. | 10 percent owner | 5050427 22.4621% | $2.12 | 0 | 2 |